Tardive dyskinesia (TD) is an involuntary movement disorder associated with prolonged use of dopamine receptor blocking agents (DRBAs) that can range in severity and presentation and can impact social, emotional, and functional components of daily life. There are treatments that can effectively manage TD, but first it needs to be recognized and accurately diagnosed.
Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration Data show clinically meaningful and.
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.